TVRD
Tvardi Therapeutics, Inc.Company Information
- Company Name
- Tvardi Therapeutics, Inc.
- CIK
- CIK0001346830
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- TVRD: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- TVRD
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2025-02-28
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 30,797
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 2,209,695
- Shares outstanding
- 9,381,344
- Ownership
- 23.55%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 0.53%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 16 | 20 | 21 | 21 | 21 | 34 | 32 | 37 | 49 | 47 | 52 | 63 | ||||||
| Debt Securities Available For Sale Excluding Accrued Interest Current | - | - | - | - | - | - | - | 5 | 7 | 23 | 49 | 16 | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | 1 | 0 | 0 | 0 | 2 | 3 | 3 | ||||||
| Inventory Net | - | - | - | - | - | 1 | 1 | 1 | 2 | 3 | 3 | 3 | ||||||
| Income Taxes Receivable | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | ||||||
| Other Receivables Net Current | - | - | - | - | - | 1 | 4 | 1 | 1 | 1 | 1 | 2 | ||||||
| Prepaid Expense Current | - | - | - | - | - | 2 | 1 | 2 | 4 | 6 | 8 | 13 | ||||||
| Restricted Cash Current | - | - | - | - | - | - | - | 2 | - | - | 0 | 0 | ||||||
| Deferred Costs | - | - | - | - | - | - | 3 | - | - | - | - | - | ||||||
| Short Term Investments | - | 5 | 10 | 15 | 20 | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 1 | 0 | 1 | 2 | 2 | - | 0 | - | - | - | - | - | ||||||
| Assets Current | 17 | 25 | 32 | 38 | 43 | - | 32 | 48 | 64 | 81 | 116 | 101 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | - | 0 | 3 | 3 | 4 | 3 | 1 | ||||||
| Intangible Assets Net Excluding Goodwill | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | - | 0 | - | 4 | 4 | 5 | 7 | ||||||
| Debt Securities Available For Sale Excluding Accrued Interest Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 5 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | ||||||
| Assets | 18 | 26 | 32 | 39 | 44 | 39 | 35 | 51 | 72 | 90 | 126 | 115 | ||||||
| Accounts Payable And Accrued Liabilities Current | - | - | - | - | - | 1 | 4 | 7 | 14 | 15 | 26 | 22 | ||||||
Liabilities Current | ||||||||||||||||||
| Restricted Cash Noncurrent | - | - | - | - | - | - | - | - | 2 | 2 | 2 | 2 | ||||||
| Royalty Guarantees Commitments Amount | - | - | - | - | - | 46 | 44 | 41 | 40 | 38 | 37 | - | ||||||
| Accounts Payable Current | 5 | 5 | 3 | 4 | 2 | - | 2 | - | - | - | - | - | ||||||
| Accrued Liabilities Current | 4 | 7 | 8 | 7 | 8 | - | 8 | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | - | 0 | 3 | 0 | 0 | - | 0 | ||||||
| Liabilities Current | 9 | 11 | 11 | 11 | 11 | 1 | 10 | 10 | 14 | 15 | 26 | 23 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | - | 0 | - | 7 | 7 | 6 | 7 | ||||||
| Convertible Long Term Notes Payable | - | - | - | - | - | - | 30 | - | - | - | - | - | ||||||
| Liabilities | 9 | 11 | 11 | 11 | 11 | 47 | 41 | 51 | 61 | 60 | 69 | - | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | 0 | 0 | 86 | 86 | 86 | 86 | - | - | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 132 | 132 | 131 | 131 | 131 | 752 | 1 | 749 | 747 | 745 | 742 | 738 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | 0 | 0 | 0 | -0 | - | - | -0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -124 | -117 | -110 | -103 | -98 | -761 | -92 | -748 | -735 | -715 | -685 | -652 | ||||||
| Stockholders Equity | 8 | 15 | 21 | 28 | 33 | -101 | -91 | -79 | -73 | 30 | 57 | 86 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities And Stockholders Equity | 18 | 26 | 32 | 39 | 44 | 39 | 35 | 51 | 72 | 90 | 126 | 115 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | 0.00 | 0.00 | - | 0.00 | - | - | - | - | - | ||||||
| Temporary Equity Shares Authorized | - | - | 0 | 0 | 0 | - | 30 | - | - | - | - | - | ||||||
| Temporary Equity Shares Issued | - | - | 0 | 0 | 0 | 4 | 4 | 4 | 4 | - | - | - | ||||||
| Temporary Equity Shares Outstanding | - | - | 0 | 0 | 0 | - | 4 | - | - | - | - | - | ||||||
Share Based Compensation Allocation And Classification In Financial Statements | ||||||||||||||||||
| Temporary Equity Liquidation Preference | - | - | 0 | 0 | 0 | - | 86 | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 17 | 58 | 200 | 200 | 100 | 8 | 100 | ||||||
| Common Stock Shares Issued | 9 | 9 | 9 | 9 | 9 | 2 | 3 | 5 | 5 | 5 | 5 | 5 | ||||||
| Shares Outstanding | 9 | 9 | 9 | 9 | 9 | 2 | 3 | 5 | 5 | 5 | 5 | 5 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTvardi Therapeutics, Inc. (TVRD) — SEC Financial Statements & Analysis
Tvardi Therapeutics, Inc. (TVRD) is a pharmaceutical preparations company, incorporated in DE. Tvardi Therapeutics, Inc. trades on Nasdaq as: TVRD. Tvardi Therapeutics, Inc. (TVRD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Tvardi Therapeutics, Inc. carries a market cap of $17.82M, a P/E ratio of -0.68x, a P/B ratio of 2.13x, a P/S ratio of 12.42x, an enterprise value of $2.06M, and an EV/EBITDA multiple of -0.08x. On profitability, it posts a gross margin of 51.52%, an operating margin of -1041.18%, a net margin of -708.99%, a Return on Equity (ROE) of -126.19%, a Return on Assets (ROA) of -85.08%, and a Return on Invested Capital (ROIC) of -244.73%. Per share, it reports EPS of $-2.78, diluted EPS of $-2.78, free cash flow per share of $-2.67, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -1010.66% year-over-year, and EPS growth of -900.50% year-over-year. On the balance sheet, it maintains a current ratio of 1.87x, a quick ratio of 1.73x, working capital of $7.96M, a debt-to-equity ratio of 1.09x, a debt ratio of 0.52, an interest coverage ratio of -316.61x, free cash flow of $-25.03M (TTM), and net debt of $-15.77M. Figures sourced from SEC EDGAR.
- Market Cap
- $17.82M
- P/E TTM
- -0.68x
- EPS TTM
- $-2.78
- P/B TTM
- 2.13x
- ROE TTM
- -126.19%
- ROA TTM
- -85.08%
- Debt To Equity
- 1.09x
- Free Cash Flow TTM
- $-25.03M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Tvardi Therapeutics, Inc. in?
Tvardi Therapeutics, Inc. (TVRD) operates in the Pharmaceutical Preparations industry.
What exchange does TVRD trade on?
Tvardi Therapeutics, Inc. (TVRD) trades on the Nasdaq.
Where is Tvardi Therapeutics, Inc. incorporated?
Tvardi Therapeutics, Inc. is incorporated in DE.
When was Tvardi Therapeutics, Inc. (TVRD)'s most recent SEC filing?
Tvardi Therapeutics, Inc. (TVRD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is TVRD's market cap?
Tvardi Therapeutics, Inc. (TVRD) has a market capitalization of $17.82M as of 2026-06-30.
What is TVRD's EPS (earnings per share)?
Tvardi Therapeutics, Inc. (TVRD)'s trailing twelve month EPS is $-2.78 as of 2026-06-30.
What is TVRD's ROE (return on equity)?
Tvardi Therapeutics, Inc. (TVRD)'s trailing twelve month Return on Equity (ROE) is -126.19% as of 2026-06-30.
What is TVRD's ROA (return on assets)?
Tvardi Therapeutics, Inc. (TVRD)'s trailing twelve month Return on Assets (ROA) is -85.08% as of 2026-06-30.
What is TVRD's ROIC (return on invested capital)?
Tvardi Therapeutics, Inc. (TVRD)'s trailing twelve month Return on Invested Capital (ROIC) is -244.73% as of 2023-12-31.
What is TVRD's EV/EBITDA?
Tvardi Therapeutics, Inc. (TVRD)'s trailing twelve month EV/EBITDA is -0.08x as of 2026-06-30.